These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21355784)

  • 1. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
    Shen S; Forero A; Meredith RF; LoBuglio AF
    Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
    J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
    Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
    Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.
    Zou P; Xu S; Povoski SP; Wang A; Johnson MA; Martin EW; Subramaniam V; Xu R; Sun D
    Mol Pharm; 2009; 6(2):428-40. PubMed ID: 19718796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.
    Leichner PK; Akabani G; Colcher D; Harrison KA; Hawkins WG; Eckblade M; Baranowska-Kortylewicz J; Augustine SC; Wisecarver J; Tempero MA
    J Nucl Med; 1997 Apr; 38(4):512-6. PubMed ID: 9098192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel monoclonal antibody design for radioimmunotherapy.
    Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF
    Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
    Chinn PC; Morena RA; Santoro DA; Kazules T; Kashmiri SV; Schlom J; Hanna N; Braslawsky G
    Cancer Biother Radiopharm; 2006 Apr; 21(2):106-16. PubMed ID: 16706631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
    Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
    Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
    Milenic D; Garmestani K; Dadachova E; Chappell L; Albert P; Hill D; Schlom J; Brechbiel M
    Cancer Biother Radiopharm; 2004 Apr; 19(2):135-47. PubMed ID: 15186593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
    Meredith R; Shen S; Macey D; Khazaeli MB; Carey D; Robert F; LoBuglio A
    Cancer Biother Radiopharm; 2003 Jun; 18(3):393-404. PubMed ID: 12954125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
    Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
    Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.